Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win
Accropeutics’ drug has hit the goals of a phase 2 psoriasis trial in China, prompting the biotech to pledge to “accelerate” the TYK2/JAK1 inhibitor’s clinical development.
Accropeutics’ drug has hit the goals of a phase 2 psoriasis trial in China, prompting the biotech to pledge to “accelerate” the TYK2/JAK1 inhibitor’s clinical development.
